1. Search Result
Search Result
Isoforms Recommended: Metallo-β-lactamase
Results for "

Metallo-β-lactamase

" in MedChemExpress (MCE) Product Catalog:

50

Inhibitors & Agonists

17

Peptides

2

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-143415

    Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-7 is a potent VIM-Type metallo-β-lactamase inhibitor with IC50s of 0.019 μM, 13.64 μM, 0.38 μM for VIM-2, VIM-1 and VIM-5. Metallo-β-lactamase-IN-7 potentiate antibacterial activity of Meropenem against the Gram-negative bacterial strains .
    <em>Metallo-β-lactamase</em>-IN-7
  • HY-163338

    Beta-lactamase Infection
    Metallo-β-lactamase-IN-13 (Compound 13i) is a pan Metallo-β-Lactamase inhibitor. Metallo-β-lactamase-IN-13 provides broader coverage of metallo-β-lactamases expressing Gram-negative (GN) bacteria. Metallo-β-lactamase-IN-13 has antibacterial activity against P. aeruginosa .
    <em>Metallo-β-lactamase</em>-IN-13
  • HY-143414

    Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-6 is a potent VIM-Type metallo-β-lactamase inhibitor with IC50s of 0.56 μM, 29.50 μM and 5.78 μM for VIM-2, VIM-1 and VIM-5. Metallo-β-lactamase-IN-6 displays potent synergistic antibacterial activity with Meropenem against engineered Escherichia coli strains and intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL .
    <em>Metallo-β-lactamase</em>-IN-6
  • HY-163339

    Beta-lactamase Infection
    Metallo-β-lactamase-IN-14 (Compound 17e) is a Metallo-β-Lactamase inhibitor. Metallo-β-lactamase-IN-14 shows inhibition activity against VIM-1 and VIM-2. Metallo-β-lactamase-IN-14 has antibacterial activity against Gram-negative (GN) bacteria and P. aeruginosa .
    <em>Metallo-β-lactamase</em>-IN-14
  • HY-146165

    Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-8 (compound 17) is a potent, reversible and competitive broad-spectrum inhibitor of metallo-β-lactamases (MβLs), with IC50s of 1.3 μM, 5.7 μM, 9.8 μM, and 9.9 μM for L1, ImiS, IMP-1 and VIM-2, respectively. Metallo-β-lactamase-IN-8 exhibits antibacterial activity .
    <em>Metallo-β-lactamase</em>-IN-8
  • HY-161094

    Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-12 is a dual inhibitor of metal β-lactamases (MβLs (NDM-1, IMP-1)) and serine β-lactamases (SβLs (OXA-48, KPC-2)), with IC50 values of 0.64 μM, 1.32 μM, 1.01 μM, and 0.57 μM, respectively. Metallo-β-lactamase-IN-12 has antibacterial activity .
    <em>Metallo-β-lactamase</em>-IN-12
  • HY-144659

    Beta-lactamase Apoptosis Bacterial Infection
    Metallo-β-lactamase-IN-5 (compound 5c) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-5 shows inhibitory activity against MBLs NDM-1 and VIM-1. Metallo-β-lactamase-IN-5 inhibits HUVECs with an IC50 of 45 μg/mL. Metallo-β-lactamase-IN-5 plus Imipenem exhibits synergistic antimicrobial activity .
    <em>Metallo-β-lactamase</em>-IN-5
  • HY-144261

    Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-3 (compound 35) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-3 shows high activity against VIM-1 and NDM-1, with IC50 of 0.6 and 1.0 μM, respectively. Metallo-β-lactamase-IN-3 does not show inhibition of IMP-7 .
    <em>Metallo-β-lactamase</em>-IN-3
  • HY-155504

    Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-11 (compound 5f) is a Metallo-β-lactamases (MBLs) inhibitor, potent against bacterial metallophyllactamase CphA (IC50=45 µM). Metallo-β-lactamase-IN-11 (10 µM) inhibits NDM-1 by 49% and AIM-1 by 61%. Metallo-β-lactamase-IN-11 can be used in the research of inhibiting antibiotic resistance .
    <em>Metallo-β-lactamase</em>-IN-11
  • HY-152105

    Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-9 (Compound 23) is a pan metallo-beta-lactamase (MBL) inhibitor with IC50s of 35, 269 and 369 nM against NDM-1, VIM-1 and IMP-1, respectively .
    <em>Metallo-β-lactamase</em>-IN-9
  • HY-144259

    Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-4 (compound 40) is a potent metallo-β-lactamases (MBL) inhibitor, with IC50 values of 0.1 μM (VIM-1), 1.3 μM (NDM-1), and 5.0 μM (IMP-7), respectively .
    <em>Metallo-β-lactamase</em>-IN-2
  • HY-144262

    Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-4 (compound 40) is a potent metallo-β-lactamases (MBL) inhibitor, with IC50 values of 0.5 μM (VIM-1), 2.1 μM (NDM-1), and 3.3 μM (IMP-7), respectively .
    <em>Metallo-β-lactamase</em>-IN-4
  • HY-161310

    Beta-lactamase Infection
    Metallo-β-lactamase-IN-15 (Compound ±13) is a potent MBL inhibitor, the IC50 values for NDM-1、IMP-1 and VIM-2 were 0.29 μM, 0.088 μM and 0.063 μM, respectively .
    <em>Metallo-β-lactamase</em>-IN-15
  • HY-136306

    Beta-lactamase Bacterial Infection
    Metallo-beta-lactamase ligand 1 is a class B β-lactamase inhibitor with antibacterial activity extracted from patent WO2019221122A1, compound A .
    <em>Metallo</em> <em>β-lactamase</em> ligand 1
  • HY-149929

    Beta-lactamase Bacterial Infection
    EBL-3183, an indole-2-carboxylate, is a potent metallo-β-lactamase (MBL) inhibitor. EBL-3183 is reversibly binding, non-covalent, competitive NDM-1 inhibitor with a pIC50 of 7.7 .
    EBL-3183
  • HY-155202

    Others Others
    YJ196 (Compound 59) is a New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor .
    YJ196
  • HY-12826

    Beta-lactamase Bcl-2 Family Bacterial Cancer
    IMB-XH1 is an inhibitor of myeloid cell factor 1 (Mcl-1) . IMB-XH1 is a non-competitive Delhi metallo-β-lactamase (NDM-1) inhibitor. The IC50s of IMB-XH1 against metallo-β-lactamases NDM-1, IMP-4, ImiS and L1 are 0.4637 μM, 3.980 μM, 0.2287 μM and 1.158 μM, respectively .
    IMB-XH1
  • HY-146637

    Beta-lactamase Bacterial Infection
    VIM-2-IN-1 (compound 1dj) is a β-lactamase inhibitor with antibacterial activities. VIM-2-IN-1 has moderate IC50 values of 23 µM, 48 µM and 231 µM for Verona integron-encoded metallo-β-lactamase (VIM-2), German imipenemase-1 (GIM-1) and New Delhi metallo-β-lactamase (NDM-1), respectively .
    VIM-2-IN-1
  • HY-162174

    Beta-lactamase Bacterial Infection
    MBL-IN-2 ((2R, 2R')-5αC) is an inhibitor of Metallo-β-lactamase (MBL) that can inhibit New Delhi Metallo-β-lactamase-1 (NDM-1) with an IC50 of 0.3 μM. MBL-IN-2 ((2R, 2R')-5αC) can be used for the study of resistance to β-lactam antibiotics .
    MBL-IN-2
  • HY-150758

    Beta-lactamase Bacterial Infection
    NDM-1 inhibitor-3 (Compound 89) is a New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor with a Ki of 4 μM .
    NDM-1 inhibitor-3
  • HY-155283

    Beta-lactamase Bacterial Infection
    Zndm19 is a New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor. Zndm19 can be used for the research of drug-resistant bacterial infections .
    Zndm19
  • HY-100871
    WT-161
    5+ Cited Publications

    Beta-lactamase HDAC Apoptosis Cancer
    WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM . WT-161 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .
    WT-161
  • HY-13428
    Tubacin
    10+ Cited Publications

    Beta-lactamase HDAC Virus Protease Cancer
    Tubacin is a potent and selective inhibitor of HDAC6, with an IC50 value of 4 nM and approximately 350-fold selectivity over HDAC1. Tubacin also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).
    Tubacin
  • HY-19328
    ACY-775
    2 Publications Verification

    HDAC Cardiovascular Disease Neurological Disease
    ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC50 of 7.5 nM . ACY775 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .
    ACY-775
  • HY-10990
    Abexinostat
    5 Publications Verification

    CRA 024781; PCI-24781

    HDAC Cancer
    Abexinostat (CRA 024781) is a novel pan-HDAC inhibitor mostly targeting HDAC1 with Ki of 7 nM. Abexinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM .
    Abexinostat
  • HY-13322
    Pracinostat
    5+ Cited Publications

    SB939

    Beta-lactamase HDAC Apoptosis Cancer
    Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC50s of 40-140 nM, used for cancer research. Pracinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM .
    Pracinostat
  • HY-144100

    Beta-lactamase Bacterial Infection
    β-Lactamase-IN-7 (compound 14) is a potent VIM-Type metallo-β-lactamase inhibitor, with Kis of 1.26 μM and 0.54 μM for VIM-1 and VIM-4, respectively. β-Lactamase-IN-7 can effectively inhibit Klebsiella pneumoniae .
    β-<em>Lactamase</em>-IN-7
  • HY-13271
    Tubastatin A Hydrochloride
    Maximum Cited Publications
    23 Publications Verification

    Tubastatin A HCl; TSA HCl

    Beta-lactamase HDAC Autophagy Apoptosis Cancer
    Tubastatin A Hydrochloride (Tubastatin A HCl) is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A Hydrochloride also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
    Tubastatin A Hydrochloride
  • HY-13271A
    Tubastatin A
    Maximum Cited Publications
    23 Publications Verification

    Beta-lactamase HDAC Autophagy Apoptosis Cancer
    Tubastatin A is a potent and selective HDAC6 inhibitor with an IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
    Tubastatin A
  • HY-13271B

    TSA TFA

    HDAC Autophagy Apoptosis Cancer
    Tubastatin A (TSA) TFA is a potent and selective?HDAC6?inhibitor with?IC50?of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A TFA also inhibits HDAC10 and metallo-β-lactamase domain-containing protein?2 (MBLAC2).
    Tubastatin A TFA
  • HY-B0368
    Captopril
    10+ Cited Publications

    SQ 14225

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Cancer
    Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
    Captopril
  • HY-B0368A

    SQ 14225 hydrochloride

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Captopril (SQ 14225) hydrochloride, antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril hydrochloride is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
    Captopril hydrochloride
  • HY-B0368S

    SQ 14225-d3

    Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Captopril-d3 is deuterium labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM[1][2][3].
    Captopril-d3
  • HY-148493

    Bacterial Infection
    MK-3402 is a metallo-beta-lactamase inhibitor (Example 303 in reference patent). MK-3402can be used in the research of bacteria .
    MK-3402
  • HY-121765

    N,S-Diacetyl-L-cysteine

    Endogenous Metabolite Metabolic Disease
    Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less New Delhi metallo-beta-lactamase-1 (NDM-1) inhibitor with an IC50 value of 1000 μM . Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .
    Dacisteine
  • HY-121765R

    N,S-Diacetyl-L-cysteine (Standard)

    Endogenous Metabolite Metabolic Disease
    Dacisteine (Standard) is the analytical standard of Dacisteine. This product is intended for research and analytical applications. Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less New Delhi metallo-beta-lactamase-1 (NDM-1) inhibitor with an IC50 value of 1000 μM . Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .
    Dacisteine (Standard)
  • HY-155104

    Beta-lactamase Bacterial Infection
    MBL-IN-1 (compound 41) is a β-Lactamase inhibitor, with the IC50 ranging from 0.10 to 25.85 µM. MBL-IN-1 can be used for research of bacterial infections .
    MBL-IN-1
  • HY-P1195

    iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide
  • HY-P1195A

    iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide TFA
  • HY-P2064

    Bacterial Infection
    Lariatins is a novel anti-mycobacterial peptides with a lasso structure produced by Rhodococcus jostii K01-B0171 .
    Lariatin A
  • HY-P2123A

    Bacterial Antibiotic Infection
    Colistin A sulfate hydrate is a major component of Colistin. Colistin is a polymyxin antibiotic and can be used to combat infections caused by problematic gram-negative bacteria .
    Colistin A sulfate hydrate
  • HY-P0227
    SHU 9119
    1 Publications Verification

    Melanocortin Receptor Metabolic Disease
    SHU 9119 is a potent human melanocortin 3 and 4 receptors (MC3/4R) antagonist and a partial MC5R agonist; with IC50 values of 0.23, 0.06, and 0.09 nM for human MC3R, MC4R and MC5R, respectively.
    SHU 9119
  • HY-106178
    PMX-53
    3 Publications Verification

    3D53

    Complement System Cardiovascular Disease Inflammation/Immunology Cancer
    PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects .
    PMX-53
  • HY-P1208

    Melanocortin Receptor Inflammation/Immunology
    PG-931, an analog of SHU 9119 (HY-P0227), is a potent melanocortin 4 (MC4) receptor (IC50=0.58 nM) agonist and is more selective than for the hMC3R (IC50=55 nM) or the hMC5R (IC50=2.4 nM). PG-931 can reverse haemorrhagic shock and prevent multiple organ damage in vivo .
    PG-931
  • HY-P1208A

    Melanocortin Receptor Inflammation/Immunology
    PG-931 TFA, an analog of SHU 9119 (HY-P0227), is a potent melanocortin 4 (MC4) receptor (IC50=0.58 nM) agonist and is more selective than for the hMC3R (IC50=55 nM) or the hMC5R(IC50=2.4 nM). PG-931 TFA can reverse haemorrhagic shock and prevent multiple organ damage in vivo .
    PG-931 TFA
  • HY-P1209A

    Melanocortin Receptor Metabolic Disease
    PG106 TFA is a potent and selective human melanocortin 3 (hMC3) receptor antagonist (IC50= 210 nM) and has noactivity at hMC4 receptors (EC50=9900 nM) and hMC5 receptor .
    PG106 TFA
  • HY-P1209

    Melanocortin Receptor Inflammation/Immunology
    PG106 is a potent and selective human melanocortin 3 (hMC3) receptor antagonist (IC50=210 nM) and has noactivity at hMC4 receptors (EC50=9900 nM) and hMC5 receptor .
    PG106
  • HY-P4910

    Proteasome Apoptosis Cancer
    Baceridin is a proteasome inhibitor and a cyclic hexapeptide. Baceridin can be isolated from the culture medium of Epiphytic Bacillus. Baceridin can inhibit cell cycle progression and induce tumor cell apoptosis through a p53-independent pathway. Baceridin can be used in cancer research .
    Baceridin
  • HY-P1108

    CFTR Others
    Astressin 2B is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC50 values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B antagonizes CRF2-mediated inhibition of gastric emptying .
    Astressin 2B
  • HY-P1108A

    CFTR Others
    Astressin 2B TFA is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC50 values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B TFA antagonizes CRF2-mediated inhibition of gastric emptying .
    Astressin 2B TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: